orthokin new approachment in molecular therapy of musculosceletal system l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
ORTHOKIN - new approachment in molecular therapy of musculosceletal system PowerPoint Presentation
Download Presentation
ORTHOKIN - new approachment in molecular therapy of musculosceletal system

Loading in 2 Seconds...

play fullscreen
1 / 20

ORTHOKIN - new approachment in molecular therapy of musculosceletal system - PowerPoint PPT Presentation


  • 600 Views
  • Uploaded on

ORTHOKIN - new approachment in molecular therapy of musculosceletal system. Dr.med. Dr.sci. Milan Marijan Pocrnja. Definition and purpose. new discipline on the base of molecular research

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'ORTHOKIN - new approachment in molecular therapy of musculosceletal system' - Jimmy


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
orthokin new approachment in molecular therapy of musculosceletal system

ORTHOKIN- new approachment in molecular therapy of musculosceletal system

Dr.med. Dr.sci.

Milan Marijan Pocrnja

slide2

Definition and purpose

  • new discipline on the base of molecular research
  • combine actual classical medical therapy with new methods from the science of the molecular biology and cell phyisiology
  • most important changes in the cell proteins structure and genetic informations
  • after exploration of human genoma with DNA analysis ,proteom analysis and vector analysis (Gentransfer-vehikel) the door for the next generation of therapy is opened

PURPOSE

Explain and threat the patologic changes on the cell level

current therapy
current therapy
  • Autologic proteins ( Orthokin®)
  • Recombined proteins
  • Gen therapy:
  • Investigation of structure and way of function of gens and proteins
    • Analyse of therapeutic molecules
    • Transfer of gens
keywords
Keywords
  • Citokyns
  • Chondral demage
  • IL-1β
  • IL-1Ra

- Interleukin1 receptor antagonist

slide5

Citokyns

  • cell-cell imunologic system transmitters
  • heterogenic nature, from different cell populations
  • could be free or on the cell
  • could act as autocrin, paracrin or endocrin
  • have a central role in the cell-cell comunication
  • samples: autokins, limfokins, chemokins, interferon, interleukins and different growth factors
difference in the functionality

Cataboliccitokins

z.B. IL-1, TNFα,

IL-17, IL-18

Anabolic citokins

Growth factors,IGF-1, TGF-βs, BMPs,

Cell

Anti-catabolic

cytokins

z.B. IL-1RA,

IL-4, IL-10, IL-13

Modulators

z.B. IL-6, IL-11

Difference in the functionality

CITOKINS

example interleukin 1
Example: Interleukin 1

Interleukin 1 (IL-1),protein of imunologic system wich has the most important role in the arthrosis , neurologic pain and cartilage distruction

Chondral destruction

Moving dissfunction

Iritation of nerves

Inflammations

orthokin therapy system make the faster production of il 1ra
Orthokin®therapy systemmake the fasterproduction of IL-1Ra

Orthokin

IL-1/IL-1Ra

1 / >140

  • Normal synovial fluid
  • IL-1/IL-1Ra
  • 1 /1

- Path.synovial fluid

IL-1/IL-1Ra

>10 / 1

  • IL-1Ra block the receptor and the bad effects of IL-1
  • making the natural balance in the imunologic system
slide12

Placebo

IL-1Ra

Placebo

IL-1Ra

Placebo

Placebo

mcilwraith frisbie
McIlwraith, Frisbie

Placebo

IL-1Ra

Frisbie, D.D., et al., Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther, 2002. 9(1): p. 12-20.

slide14

Pain reduction in arthrosis

Gelenk - Studie Uni-Düsseldorf (05 / 2005)

VAS score of pain in the Orthokin® patients(n=143)was lower for 31% more than in the patients with therapy ofHialuronyc acid.- (n=138) and in Placebo-group (n=118).

p<0,001*

P>0,05**

* p<0,001 za usporedbu

Orthokin® vs. HA i P

®

Hya-Ject®

NaCl

** p> 0,05 za usporeduHA vs. P

VAS Scores (%) reduction after 26 weeks

slide16

Production process of the

autologic conditioned serum – ORTHOKIN

slide17

Indication for Orthokin®therapy

Acute and chronic joint diseases of musculosceletal system:

gonarthrosis, coxarthrosis, shoulder arthrosis, as chondral trauma demages, lumboischialgy, traumatic muscular and tendon ruptures, etc.

slide18

Orthokin® – therapy :joints

Orthokin®- directly intraarticulary

Dose: 1 injections 2 ccm per week for 5 weeks

slide19

Orthokin® - Terapija:Lumboishialgy

Orthokin®- directly on the radicular

Dose: 1 injections 2 ccm per week for 3 weeks

for informations about orthokin therapy please contanct
For informations about Orthokin therapy please contanct :

ALFA - ARTHRO d.o.o.

Športska 26

Varaždin

www.alfa-arthro.hr